Menu di pagina
- IRE Research and Technology
- IRE Competitive Grants
- PerfeTTO
- INNOVA
- Immune Metabolism Dysregulation and Efficacy of Anti-PD-1/PD-L1 Agents in Non-Small Cell Lung Cancer (NSCLC)
- Artificial Intelligence and Machine Learning Based Risk Prediction Model for Improving Endometrial Cancer Clinical Management
- Low-Intensity Extracorporeal Shockwave Therapy on Penile Rehabilitation after robot-assisted surgical treatment of genitourinary cancers
- Deciphering KEAPness for Improved Immunotherapy Prediction and Treatment
- MiRNA-based therapeutic approach to fight triple negative breast cancer
- Beyond the creation of a living biobank: dissecting the transcriptomic landscape of Gastro-entero-pancreatic neuroendocrine neoplasms
- Multidimensional assessment of virus-associated head and neck cancer patients for the discovery of predictive biomarkers to guide clinical intervention
- TArgeting drug resistant melanoma with miCroRNAs delivered by Lipid NanoparTICles (TACTIC)
- Addressing liver fibrosis prevention and treatment: an unbiased query on the hepatic microenvironment with a perspective targeting of the pro-fibrotic kinase HIPK2
- Analyses of HPV and host body fluid biomarkers as non-invasive strategy for detection of head and neck cancer relapse
- Deciphering Biology of R/R DLBCL Subtypes: miRNA Biomarkers for Optimizing Treatment and Survival
- Clinically approved drugs targeting pyruvate kinase M2: a drug repurposing pathway to move forward the treatment of glioblastoma
- Developing a Biobank Network Among Major Sarcoma Treatment Centers to Improve Biomedical Research
- Identification and Validation of Prognostic and Predictive Biomarkers, Including E3 Ubiquitin Ligases and MicroRNA Signature, for the Development of New Immunotherapeutic Approaches in Glioma
- Heal Italia
- D3 4 Health
- TRIglIFO2 project
- Poc MIMIT Project
- The PROMlSE project
- The 4Immunogenomics project
- Project ERBB2
- Project NANO-COVID-TEST
- Progetto DOMINO – Lazio Innova
- Project GEMMA – Lazio Innova
- Project COMETA
- Exploring the role of Bcl-2 family in the immune surveillance of melanoma: from mechanisms to therapeutic perspectives
- Exploring how endothelin-1/PIEZO axis intersects mechanical forces to fuel PARP inhibitor resistance in ovarian cancer
Identification and Validation of Prognostic and Predictive Biomarkers, Including E3 Ubiquitin Ligases and MicroRNA Signature, for the Development of New Immunotherapeutic Approaches in Glioma
Project description
PI: Antonietta Arcella, Istituto Neurologico Mediterraneo Neuromed
IRE Principal Collaborators Involved: Maria Giulia Rizzo
Project duration: 24 months
Project code: PNRR-TR1-2023-12377378
The project aims to identify and validate novel molecular biomarkers with prognostic value and predictive of treatment response, focusing on E3 ubiquitin ligases and microRNAs in gliomas. Gliomas are rare malignant brain tumors with poor prognosis due to their infiltrative growth and resistance to treatments.
Purpose
To identify and validate E3 ubiquitin ligases and microRNAs as prognostic and predictive biomarkers.
To explore their role in glioma biology and their interaction with the immune microenvironment.
To develop innovative immunotherapeutic approaches to enhance the effects of standard chemotherapy in gliomas.
Expected Outcomes
Identification of E3 ubiquitin ligases as biomarkers: Investigate the role of MEX3A and RNF182 in glioma prognosis and their potential as therapeutic targets.
MicroRNA signature profiling: Identify and validate specific microRNA signatures with prognostic value and their role in modulating the tumor microenvironment.
Preclinical validation: Use in vitro and in vivo models to validate the identified biomarkers and their impact on glioma development and immune response.
Specific Aims:
E3 Ubiquitin Ligases: Characterize the role of MEX3A and RNF182 in glioma prognosis and their potential as therapeutic targets.
MicroRNA Signatures: Identify and validate microRNA signatures with prognostic value and their role in modulating the tumor microenvironment.
Preclinical Models: Validate the role of identified biomarkers in glioma development and immune response using in vitro and in vivo models.
Financial Support
PNRR, financed by Ministero della Salute
The total grant of the project is: € 1.000.000,00
The grant assigned to IFO – IRE is: € 290.000,00
Other Institution involved: Università di Roma La Sapienza, Università degli Studi del Molise
The funding resources are from the public notice 2° Avviso pubblico per la presentazione e selezione di progetti di ricerca da finanziare nell’ambito del PNRR sulle seguenti tematiche:
- Proof of concept (PoC);
- Tumori Rari (TR);
- Malattie Rare (MR);
- Malattie Croniche non Trasmissibili (MCnT) ad alto impatto sui sistemi sanitari e socio-assistenziali:
- Innovazione in campo diagnostico,
- Innovazione in campo terapeutico;
- Malattie Croniche non Trasmissibili (MCnT) ad alto impatto sui sistemi sanitari e socio-assistenziali:
- Fattori di rischio e prevenzione,
- Eziopatogenesi e meccanismi di malattia
Piano Nazionale di Ripresa e Resilienza - Missione M6 - Componente C2 - Investimento 2.1 Valorizzazione e potenziamento della ricerca biomedica del SSN finanziato dall’Unione europea - NextGenerationEU.